Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 7:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: orlistat Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Effectiveness of Brief Counseling for Weight Management

NCT00212199
View directory record Official record
Conditions
1. Obesity
Interventions
orlistat, Brief cognitive behavioral counseling
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
25 Years to 55 Years
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2010 · Synced Oct 29, 2026, 7:17 AM EDT
Completed Phase 4 Interventional Results available

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity

NCT03799198
View directory record Official record
Conditions
Obesity
Interventions
Weight Management Program (WMP), Medication for chronic weight management (Rx)
Other · Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 29, 2026, 7:17 AM EDT
Active, not recruiting No phase listed Observational

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

NCT07188545
View directory record Official record
Conditions
Cardiovascular Kidney Metabolic Syndrome
Interventions
Intervention, Active Comparator
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
23,280,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 29, 2026, 7:17 AM EDT
Terminated Phase 2 Interventional Results available

Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity

NCT01351753
View directory record Official record
Conditions
Obesity, Metabolic Syndrome X
Interventions
Metformin, Orlistat, Topiramate, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
40 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 29, 2026, 7:17 AM EDT
Terminated Phase 4 Interventional

Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding

NCT01597531
View directory record Official record
Conditions
Type 2 Diabetes, Gastric Banding
Interventions
Liraglutide, Orlistat, Liraglutide + Orlistat
Drug
Lead sponsor
East Carolina University
Other
Eligibility
25 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 29, 2026, 7:17 AM EDT
Recruiting Phase 2 Interventional

Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia

NCT05816343
View directory record Official record
Conditions
Type 1 Hyperlipoprotenemia
Interventions
Orlistat, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 29, 2026, 7:17 AM EDT
Completed Phase 4 Interventional Results available

A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.

NCT01035333
View directory record Official record
Conditions
Obesity
Interventions
Orlistat
Drug
Lead sponsor
Albany College of Pharmacy and Health Sciences
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2014 · Synced Oct 29, 2026, 7:17 AM EDT
Completed Phase 4 Interventional

Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus

NCT00207311
View directory record Official record
Conditions
Fatty Liver, Hepatitis C
Interventions
Xenical, Pegasys, Copegus, Xenicare Program
Drug · Behavioral
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 29, 2026, 7:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Fat Perception in Humans (09-0873)

NCT01128400
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 29, 2026, 7:17 AM EDT
Completed Phase 4 Interventional

Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)

NCT00160407
View directory record Official record
Conditions
Fatty Liver, Hepatitis
Interventions
Orlistat (Xenical), 1400 kcal diet (30% fat)
Drug · Behavioral
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
St Louis, Missouri • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2007 · Synced Oct 29, 2026, 7:17 AM EDT
Completed Phase 2 Interventional

Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects

NCT01126970
View directory record Official record
Conditions
Obesity
Interventions
Velneperit 400 mg, Orlistat 120 mg, Orlistat Placebo, Velneperit Placebo, Reduced Calorie Diet
Drug · Other
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Santa Rosa, California • Waterbury, Connecticut • Clearwater, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 29, 2026, 7:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Orlistat in Body Composition

NCT00752726
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Orlistat, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Baton Rouge, Louisiana • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 29, 2026, 7:17 AM EDT
Completed Phase 3 Interventional Results available

Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility

NCT02432209
View directory record Official record
Conditions
Infertility, Female
Interventions
Caloric Restriction, Orlistat, Moderate physical activity
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
10
States / cities
San Francisco, California • Augusta, Georgia • Southfield, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Oct 29, 2026, 7:17 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia

NCT01675154
View directory record Official record
Conditions
Type 1 Hyperlipoproteinemia
Interventions
SLx-4090 placebo, Orlistat Placebo, Orlistat, Slx-4090
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 29, 2026, 7:17 AM EDT
Not listed Phase 2 Interventional

Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea

NCT02069197
View directory record Official record
Conditions
Obesity, Diabetes, Obstructive Sleep Apnea
Interventions
Ketogenic diet, Orlistat, Standardized diet
Other · Drug
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 29, 2026, 7:17 AM EDT
Completed Phase 4 Interventional Results available

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

NCT05579249
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 29, 2026, 7:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss

NCT00108524
View directory record Official record
Conditions
Diabetes Mellitus, Obesity
Interventions
Low carbohydrate ketogenic diet, Orlistat, Low-fat diet
Behavioral · Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 69 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 29, 2026, 7:17 AM EDT
Completed Phase 2 Interventional Results available

Orlistat for the Treatment of Type I Hyperlipoproteinemia

NCT02767531
View directory record Official record
Conditions
Hyperlipoproteinemia Type I, Hypertriglyceridemia
Interventions
Orlistat
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 29, 2026, 7:17 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Effect of Modified Sham Feeding With Orlistat in Overweight and Obese Subjects

NCT01719419
View directory record Official record
Conditions
Overweight
Interventions
Placebo, Orlistat
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2015 · Synced Oct 29, 2026, 7:17 AM EDT
Terminated Phase 4 Interventional Results available

LOSS- Louisiana Obese Subjects Study

NCT00115063
View directory record Official record
Conditions
Obesity
Interventions
group sessions, sibutramine, orlistat, diethylpropion, Low Calorie Diet, Health One, Intensive Medical Combination Therapy for Obesity, Control Condition
Behavioral · Drug · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 60 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 29, 2026, 7:17 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases

NCT00001723
View directory record Official record
Conditions
Diabetes Mellitus, Hypertension, Metabolic Disease, Obesity, Sleep Apnea Syndrome
Interventions
Orlistat, Placebo
Drug
Lead sponsor
Jack Yanovski
NIH
Eligibility
12 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 29, 2026, 7:17 AM EDT
Terminated Not applicable Interventional Results available

Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients

NCT00871845
View directory record Official record
Conditions
Obesity, Insulin Resistance, Metabolic Syndrome, Hepatitis C
Interventions
Dietary and Lifestyle modification educational sessions
Behavioral
Lead sponsor
Hossam Kandil
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 29, 2026, 7:17 AM EDT
Enrolling by invitation No phase listed Observational

A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy

NCT05503927
View directory record Official record
Conditions
Pregnancy, Obesity, Overweight
Interventions
No Intervention
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
2,701 participants
Timeline
2020 – 2027
U.S. locations
2
States / cities
Ann Arbor, Michigan • Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 29, 2026, 7:17 AM EDT
Terminated Not applicable Interventional Results available

Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia

NCT00794963
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan, As selected by community physician
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
19 Years to 79 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 29, 2026, 7:17 AM EDT